Dravet syndrome

FDA pushes back decision on Zogenix epilepsy drug
FDA pushes back decision on Zogenix epilepsy drug
BioPharma Dive
Zogenix
epilepsy
Fintepla
FDA
Dravet syndrome
Flag link:
New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug
New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug
BioSpace
Zogenix
Fintepla
Dravet syndrome
epilepsy
Flag link:
Why Shares of Drugmaker Zogenix Dropped 11.4% in August
Why Shares of Drugmaker Zogenix Dropped 11.4% in August
Motley Fool
Zogenix
Fintepla
Dravet syndrome
Flag link:
Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike
Endpoints
Zogenix
FDA
Dravet syndrome
Fintepla
Flag link:
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Xconomy
Stoke Therapeutics
IPOs
Dravet syndrome
Flag link:
Stoke Therapeutics Files for $86 Million IPO
Stoke Therapeutics Files for $86 Million IPO
CP Wire
Stoke Therapeutics
Dravet syndrome
IPOs
Flag link:
Stoke Therapeutics Files for $86 Million IPO
Stoke Therapeutics
Dravet syndrome
Flag link:
FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
Endpoints
Zogenix
Dravet syndrome
FDA
refuse to file letters
Flag link:
Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?
Motley Fool
GW Pharma
Epidiolex
Cannabidiol
clinical trials
Dravet syndrome
Flag link:
GW announces US launch of cannabinoid medicine for seizures
GW announces US launch of cannabinoid medicine for seizures
Pharmaceutical Business Review
GW Pharma
Greenwich. Epidiolex
drug launches
Dravet syndrome
Lennox-Gastaut Syndrome
Flag link:
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Xconomy
Dravet syndrome
clinical trials
Zogenix
ZX008
FenPhen
GW Pharma
Epidiolex
Flag link:
FDA approves country’s first medicine made from marijuana
FDA approves country’s first medicine made from marijuana
Stat
GW Pharma
Epidiolex
epilepsy
FDA
Dravet syndrome
Lennox-Gastaut Syndrome
marijuana
Flag link:
This Cannabis-Based Drug Is On the Verge of Making History
This Cannabis-Based Drug Is On the Verge of Making History
Motley Fool
GW Pharma
Epidiolex
CBD
Dravet syndrome
Lennox-Gastaut Syndrome
FDA
Flag link:
Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’
Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’
Endpoints
Zogenix
FDA
epilepsy
Dravet syndrome
ZX008
breakthrough therapies
Flag link:
3 Biotech Stocks With Big News Coming
3 Biotech Stocks With Big News Coming
Motley Fool
biotech
Flexion
Zilretta
osteoarthritis of the knee
Zogenix
ZX008
Dravet syndrome
Keryx
chronic kidney disease
Auryxia
Flag link:
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
Motley Fool
Zogenix
GW Pharma
Sativex
Epidiolex
LGS
Dravet syndrome
Flag link:
GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy
GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy
Xtalks
GW Pharma
cannabis
clinical trials
Epidiolex
epilepsy
Dravet syndrome
Flag link:
Zogenix says former obesity drug reduced seizures in study
Zogenix says former obesity drug reduced seizures in study
Yahoo/Reuters
Zogenix
obesity
seizures
fenfluramine
Dravet syndrome
Flag link:
GW Pharma receives FDA fast-track designation for Dravet syndrome treatment
GW Pharma receives FDA fast-track designation for Dravet syndrome treatment
Reuters
FDA
GW Pharma
fast track
Dravet syndrome
Epidiolex
Flag link: